The absorption of the drug is unaffected by the site of injection [12]. The pharmacokinetics of luspatercept are independent of age, gender, race, ethnicity, hepatic or renal impairment, RBC transfusion burden, baseline serum albumin or erythropoietin levels, beta-thalassemia genotype (β0/β0 vs. non - β0/β0), splenectomy, or the concomitant use of iron chelating agents [12-13]. Here, EPO is linked to beta thalassemia.